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REVIEWWhich high-risk HPV assays fulﬁl criteria for use in primary cervical cancer
screening?M. Arbyn1, P. J. F. Snijders2, C. J. L. M. Meijer2, J. Berkhof3, K. Cuschieri4, B. J. Kocjan5 and M. Poljak5
1) Unit of Cancer Epidemiology and Belgian Cancer Centre, Scientiﬁc Institute of Public Health, Brussels, Belgium, 2) Department of Pathology, 3) Department of
Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands, 4) Scottish HPV Reference Laboratory, Royal Inﬁrmary of
Edinburgh, Edinburgh, Scotland, UK and 5) Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, SloveniaAbstractSeveral countries are in theprocessof switching tohigh-risk humanpapillomavirus (hrHPV) testing for cervical cancer screening.Given themultitude
of available tests, validated assays which assure high-quality screening need to be identiﬁed. A systematic review was conducted to answer the
question which hrHPV tests fulﬁl the criteria deﬁned by an international expert team in 2009, based on reproducibility and relative sensitivity
and speciﬁcity compared to Hybrid Capture-2 or GP5+/6+ PCR–enzyme immunoassay. These latter two hrHPV DNA assays were validated in
large randomized trials and cohorts with a follow-up duration of 8 years or more. Eligible studies citing the 2009 guideline were retrieved from
Scopus (http://www.scopus.com) and from a meta-analysis assessing the relative accuracy of new hrHPV assays versus the standard comparator
tests to detect high-grade cervical intraepithelial neoplasia or cancer in primary screening. The cobas 4800 HPV test and Abbott RealTime High
Risk HPV test were consistently validated in two and three studies, respectively, whereas the PapilloCheck HPV-screening test, BD Onclarity
HPV assay and the HPV-Risk assay were validated each in one study. Other tests which partially fulﬁl the 2009 guidelines are the following:
Cervista HPV HR Test, GP5+/6+ PCR-LMNX, an in-house E6/E7 RT quantitative PCR and MALDI-TOF (matrix-assisted laser desorption-
ionization time-of-ﬂight). The APTIMA HPV assay targeting E6/E7 mRNA of hrHPV was also fully validated. However, the cross-sectional
equivalency criteria of the 2009 guidelines were set up for HPV DNA assays. Demonstration of a low risk of CIN3+ after a negative APTIMA
test over a longer period is awaited to inform us about its utility in cervical cancer screening at 5-year or longer intervals.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: marc.arbyn@wiv-isp.beIntroductionA high level of evidence is currently available indicating that
human papillomavirus (HPV)-based cervical cancer screening is
more effective and efﬁcient for the prevention of invasive
cervical cancer and mortality from cervical cancer than
screening with the Papanicolaou test [1,2]. Four EuropeanClinical Microbiology and Infection © 2015 European Society of Crandomized trials have demonstrated that the cumulative inci-
dence of cervical cancer 5 years after a negative HPV test was
lower than the incidence 3 years after a normal cytology result
[3]. The HPV assays used in these trials were the Hybrid
Capture-2 (HC2) and the GP5+/6+ PCR–enzyme immunoassay
(EIA). Moreover, longitudinal follow-up data of screened co-
horts indicate a very low risk of developing cervical precancer
or cancer over 8 years or more in women with a negative HC2
or GP5+/6+ PCR-EIA test [1,4–8]. Therefore, these two HPV
assays are considered as fully clinically and epidemiologically
validated [9]. HC2 (Qiagen, Gaithersburg, MD, USA) uses
captured RNA probes which hybridize with viral DNA of 13
high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59 and 68). Captured HPV RNA/DNA hybrids are identiﬁedClin Microbiol Infect 2015; 21: 817–826
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.04.015
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signal, the intensity of which is related to viral load [10]. HC2
does not involve DNA ampliﬁcation. The GP5+/6+ PCR-EIA
uses a single pair of consensus primers targeting a conserved
DNA sequence of 140 bp of the L1 gene of HPV. After ampli-
ﬁcation, a hybridization step with type-speciﬁc probes followed
by EIA-based detection of hybrids can identify 14 HPV types
(the same types targeted by HC2, plus HPV 66) [11].
Within the last decade, over 125 HPV assays (and over 80
variants of the original assays) have been developed, but evi-
dence of their clinical utility has been demonstrated for rela-
tively few [1,12,13]. In 2009, an international team of experts
proposed criteria for assay validation in primary screening
contexts based on minimal relative clinical accuracy of a given
HPV assay compared to HC2 or GP5+/6+ PCR-EIA and mini-
mal intra- and interlaboratory reproducibility [9]. The purpose
of this review was to verify which tests fulﬁl these criteria.MethodsResearch question
This systematic review aims to answer the question which HPV
tests can be considered to be clinically validated for use in
primary cervical cancer screening. The PICOS (population–
intervention–comparator–outcome–study) components can
be found in the online Supplementary Material.
Literature retrieval
A search was conducted in Scopus (http://www.scopus.com) to
identify reports that cited the guideline containing the equiva-
lency criteria of Meijer et al. [9]
As a consequence of the preparation of new guidelines on
secondary prevention of cervical cancer screening in Europe,
and more recently in the Netherlands, Germany and Belgium,
previously published meta-analyses on the diagnostic accuracy
of HPV testing in primary screening were updated [1,14]. The
search string used to retrieve references is provided in the
online Supplementary Material. Details on the selection of
relevant references can be found in previously published re-
ports [1,15]. Studies were selected when the accuracy for
cervical intraepithelial neoplasia of grade 2 or worse (CIN2+)
or CIN3+ of HC2 or GP5+/6+ PCR-EIA was compared with
cytology and with another high-risk (hr) HPV assay detecting
hrHPV types in cervical samples taken from women attending
cervical cancer screening. Women with at least one positive
screening test had to be veriﬁed with the reference standard
(colposcopy and histology). Co-test-negative cases were
considered as truly negative, accepting the assumption that the
probability of missing cervical precancer was very low [1,6].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectFinally, the Cervix1 bibliographic database of the Unit of
Cancer Epidemiology (IPH Brussels) was consulted. Cervix1
contains almost 30000 literature references largely related to
cervical cancer and HPV. The quality of the selected studies was
evaluated using the QUADAS-2 checklist [16]. The results of
the HPV assays with individual genotyping were assessed for the
presence or absence of hrHPV types according to the pool of
13 or 14 high-risk types in common with the types targeted by
HC2 (HPV 16, 18, 31, 33, 45, 51, 52, 56, 58, 59, 68) or GP5+/
6+ PCR-EIA (same types plus HPV 66).
Equivalency criteria
In 2009 an international expert committee proposed that a new
hrHPV DNA assay should be at least as accurate as the HC2 or
GP5+/6+ PCR-EIA, and should be highly reproducible in order to
be eligible for use in cervical cancer screening. The candidate test
should demonstrate a relative sensitivity and speciﬁcity to detect
CIN2+ compared to one of the aforementioned standard
comparator tests of 0.90 and 0.98, respectively [9]. A repre-
sentative set of consecutively collected samples should be selected
(minimally 60 CIN2+ cases, 800 CIN1 cases) derived from a
population-based screening cohort of women aged 30 to 60 years
[9]. Thep value for a noninferiority score test shouldbe lower than
0.05 [17]. In addition, a high inter- and intrareproducibility (lower
conﬁdence bound [LCIB] 87%) should be reached. For each
retrieved validation study, fulﬁllment of these criteriawas checked.
Meta-analysis
A meta-analysis of the relative sensitivity and speciﬁcity of the
new HPV assay versus one of the two standard comparator
HPV tests was conducted using a random-effects model for
pooling ratios of proportions [18]. Forest plots, with subgroups
at the level of individual tests, were drawn. Whether the
conﬁdence interval (CI) included unity and the LCIB was equal
to or exceeded 0.90 for sensitivity or 0.98 for speciﬁcity was
assessed to determine noninferiority of the new test compared
to the standard comparator test.
In order to assure comparable inference, 90% CIs around
the relative accuracy measures were computed which show a
statistical coverage similar to that of the one-sided non-
inferiority testing at p < 0.05.
Although equivalency criteria have been deﬁned only for the
CIN2+ outcome, we have extracted the relative accuracy
values also at the level of CIN3+.ResultsOne hundred ninety-seven references were retrieved in Sco-
pus; 11 of them contained data that ﬁtted the Meijer validationious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 817–826
TABLE 1. Characteristics of hrHPV tests validated using cross-sectional equivalence performance criteria
hrHPV assay
Nucleic acid
targeted
Type of
ampliﬁcation Genes targeted Separate genotyping Internal control for human genes
Standard comparator tests
* HC2 DNA Signal Whole viral
genome
No No
* GP5+/6+ PCR-EIA DNA Target L1 No No
HPV assays validated according to the Meijer protocol
1 APTIMA HPV assay [26] RNA Target E6/E7 No (a prototype identifying HPV16, 18–45 exists) No. Assay includes internal controls
for non-infectious RNA and DNA.
2 Abbott RealTime High Risk HPV test [20–22] DNA Target L1 16,18 & 12 other hr types β-globin
3 BD Onclarity HPV assay [30] DNA Target E6/E7 16,18,31,45,51,52;
33–58; 56–59–66; 35–39–68
β-globin
4 Cervista HPV HR Test [27,28] DNA Signal L1/E6/E7 14 hr types. Separate typing of 16, 18 available as a reﬂex test. human histone 2
5 cobas 4800 HPV test [23,24] DNA Target L1 16,18 & 12 other hr types (see HC2 plus 66) β-globin
6 qPCR(E6/E7) [25] DNA Target E6/E7 Separate typing of hrHPV types 16,18,31,33, 35,39,45,51,52,56,58,59,66,68;
phr type 53 and lr types 6 & 11.
β-globin
7 HPV-Risk assay [29] DNA Target E7 16, 18 and 13 other hr types (see HC2 plus 66 & 67) β-globin
8 PapilloCheck HPV-screening test [19] DNA Target E1 Separate typing of 16,18,31,33,35,39,45,51,52,53,56,58,59,66,68.
As well as phr types 70,73,82 and lr types
6,11,40,42,43,44.
ADAT1
HPV assays assessed in cross-sectional studies in a primary screening setting or according to the VALGENT protocol
1 GP5+/6+-LMNX [41] DNA Target L1 Separate typing of hr HPV types 16,18,31,33,35,39,45,51,52,56,58,59,66,68;
Detects also phr types: 26,53,73,82.
Human DNA fragment located on chromosome 14
2 careHPV Test [38] DNA Signal Whole viral
genome
No No
3 MALDI-TOF [40] DNA Target L1 Separate typing of hr HPV types 16,18,31,33,35,39,45,51,52,56,58,59,66,68. β-globin
4 Pretect HPV-Proofer [55] RNA Target E7/E7 Yes (16,18,31,33,45) U1 small nuclear ribonucleo-protein-speciﬁc mRNA.
hrHPV, high-risk human papillomavirus; ADAT1 gene, adenosine deaminase, tRNA speciﬁc 1; phr, potentially high-risk type; qPCR, quantitative PCR; MALDI-TOF, matrix-assisted laser desorption-ionization time-of-ﬂight.
* HC2 and GP5+/6+ PCR-EIA are clinically validated in randomised efﬁcacy trials and therefore used as standard comparator tests to validate other HPV assays.
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TABLE 2. Sensitivity and speciﬁcity of hrHPV assays validated for cervical cancer screening, relative sensitivity and speciﬁcity of the
evaluated hrHPV assays compared to the standard comparator tests (HC2 or GP5+/6+ PCR-EIA)
Evaluated assay Comparator assay
Evaluated/
comparator
assay
Non-inferiority
test*
Validation
level‡
Evaluated
assay Study
Absolute
Comparator
assay
Absolute Relative
sensitivity speciﬁcity sensitivity speciﬁcity sensitivity speciﬁcity psens pspec
GP5+/6+ EIA Meijer, 2009 [9] 98.7% 96.0% HC2* 98.7% 94.1% 1.00 1.02 0.0037 <0.0001 4444
PapilloCheck Hesselink, 2010 [19] 95.8% 96.7% GP5+/6+ EIA 96.4% 97.7% 0.99 0.99 <0.0001 0.0072 44
Abbott RT Carozzi, 2011 [20] 96.4% 92.3% HC2 97.6% 92.6% 0.99 1.00 0.0040 0.0087 444
hrHPV test Poljak, 2011 [21] 100.0% 93.3% HC2 97.4% 91.8% 1.03 1.02 0.0112 0.0000
Hesselink, 2013 [22] 95.6% 92.0% GP5+/6+ EIA 98.5% 91.8% 0.97 1.00 0.0278 0.0003
cobas 4800 Heideman, 2011 [23] 90.0% 94.6% HC2 91.7% 94.4% 0.98 1.00 0.0216 0.0009 444
Lloveras, 2013 [24] 98.3% 86.2% HC2 98.3% 85.3% 1.00 1.01 0.0093 0.0012
qPCR(E6/E7) Depuydt, 2012 [25] 93.5% 95.6% HC2 83.9% 94.4% 1.11 1.01 0.0001 <0.0001 44
APTIMA Heideman, 2013 [26] 95.5% 94.5% GP5+/6+ EIA 100.0% 93.6% 0.96 1.01 0.0394 0.0002 x
Cervista Boers, 2014 [27] 89.0% 91.2% HC2 93.4% 88.8% 0.95 1.03 0.0043 <0.0001 4
Alameda, 2015 [28] 98.4% 85.2% HC2 100.0% 86.4% 0.98 0.99 0.0122 0.3170†
BD Onclarity Ejegod, 2014 [30] 92.9% 87.7% HC2 94.2% 88.8% 0.99 0.99 0.0009 0.0216 44
HPV-Risk assay Hesselink, 2014 [29] 97.1% 94.3% GP5+/6+ EIA 97.1% 94.1% 1.00 1.00 0.0056 0.0003 44
* p values for non-inferiority of the evaluated assay compared to the comparator assay.
† We corrected an error in Alameda, 2015 [28] (due to switching of + and – columns and rows). The corrected data showed that the non-inferiority test was not signiﬁcant for
speciﬁcity.
‡Validation level for the test accuracy criterion as proposed by Meijer et al 2009 [9].
4444 validated in large randomized controlled trials with cancer incidence as an outcome; considered as standard comparator tests.
444: fully validated in multiple studies.
44 fully validated in one study.
4 partially validated.
X not evaluated since not a hrHPV DNA assay.
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[19–29]. A 12th reference was retrieved from the Cervix1
database [30]. Eight candidate hrHPV assays were evaluated
(PapilloCheck HPV-screening test [19]; Abbott RealTime High
Risk HPV test [Abbott RT hrHPV test] [20–22]; cobas 4800
HPV test [23,24]; an in-house quantitative PCR [qPCR] tar-
geting the E6 or E7 HPV genes [25]; APTIMA HPV assay [26];
Cervista HPV HR Test [27,28]; BD Onclarity HPV assay [30];
and the HPV-Risk assay [29]) (Supplementary Table S2). The
test characteristics are listed in Table 1. Details about the study
design and characteristics are provided in Supplementary
Table S3. Data on intra- and interlaboratory reproducibility of
the PapilloCheck HPV-Screening test were retrieved from an
online source (http://www.pathology.nl) [31].
Using the Meijer validation protocol, ﬁve HPV DNA assays
(PapilloCheck HPV-Screening test; Abbott RT hrHPV test; cobas
4800 HPV test; BD Onclarity HPV assay; HPV-Risk assay) and
the APTIMA assay, targeting E6/E7 mRNA, fulﬁlled all the
equivalency criteria (Tables 2 and 3). For the Abbott RT hrHPV
test and the cobas 4800 HPV test, respectively, three [20–22]
and two studies [23,24] consistently conﬁrmed equivalency forClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectaccuracy and high reproducibility. The Cervista HPV HR Test
also fulﬁlled all the criteria in one study [27], but in another
study, inferior speciﬁcity compared to HC2 could not be
rejected (pn.inf 0.3170) [28]. The in-house E6/E7 qPCR fulﬁlled
the criteria for accuracy and intralaboratory reproducibility, but
interlaboratory reproducibility was not reported [25].
The meta-analysis of the relative accuracy for CIN2+ included
(besides the 12 aforementioned validation studies) 10 additional
reports evaluating HPV tests in primary screening [21,32–40] as
well as one validation study designed according to the VAL-
GENT protocol (see chapter 6 of Supplementary Materials) [41].
In total, 22 comparisons with HC2 and 4 with GP5+/6+ PCR-EIA
were noted involving 12 assays. The four assays not included in
the retrieval of the Meijer validation studies were careHPV Test
[38,39], Pretect HPV-Proofer (E6/E7 mRNA assay) [36],
MALDI-TOF (matrix-assisted laser desorption-ionization time-
of-ﬂight) [40] and an alternative GP5+/6+ PCR with Luminex-
based identiﬁcation of separate HPV types (LMNX Genotyping
Kit HPV GP) [41] (Table 1). For the MALDI-TOF, only accuracy
for CIN3+ was reported, but data for the end point of CIN2+
was provided by the author upon request [40]. Supplementaryious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 817–826
TABLE 3. Intra- and inter-laboratory reproducibility of hrHPV assays validated for cervical cancer screening
Evaluated Assay Study
Intra-laboratory reproducibility (hr
HPV DNA)
Inter-laboratory reproducibility
(hrHPV)
Validation Level‡Overall LCIB Kappa Overall LCIB Kappa
PapilloCheck Hesselink, 2010 [19] 97.6% 96.3% 0.941 94.0% 92.1% 0.842 44
Abbott RT
hrHPV test
Carozzi, 2011 [20] 98.5% 97.3% 0.969 – – – 44
Poljak, 201 [21]1 100.0% 99.5% 1.000 100.0% 99.5% 1.000
Hesselink, 2013 [22] 99.8% 99.1% 0.996 98.4% 97.2% 0.965
cobas 4800 Heideman, 2011 [23] 98.3% 97.2% 0.963 94.6% 92.8% 0.882 44
Lloveras, 2013 [24] 98.3% 97.2% 0.963 98.4% 97.2% 0.962
qPCR(E6/E7) Depuydt, 2012 [25] 98.7% 97.8% 0.956 – – – 4
APTIMA Heideman, 2013 [26] 96.0% 94.4% 0.893 95.1% 93.3% 0.865 44
Cervista Boers, 2014 [27] 91.9% 89.7% 0.829 90.7% 88.4% 0.807 44
Alameda, 2015 [28] 94.9% 93.0% 0.890 96.5% 94.9% 0.907
BD Onclarity Ejegod, 2014 [30] 98.6% 97.5% 0.967 98.4% 97.2% 0.962 44
HPV-Risk assay Hesselink, 2014 [29] 99.5% 97.3% 0.987 99.2% 97.2% 0.981 44
hrHPV: high-risk human papillomavirus; LCIB: lower 95% conﬁdence interval bound; RT:real time; qPCR: quantitative polymerase chain reaction.
‡Validation level for the reproducibility criterion: 44 high intra- and inter-laboratory reproducibility conﬁrmed; 4 high intra-laboratory reproducibility conﬁrmed. Tests are
validated as proposed by Meijer et al 2009 [9].
CMI Arbyn et al. HPV assays and cervical cancer screening 821Table S4 summarizes the methodologic quality of the ten
included screening studies, which was overall moderate to
good with average negative scores for the 13 QUADAS-2
items varying between 0% and 15%, equivocal scores varying
between 0% and 31% and positive scores varying between 54%
and 100%.
The relative sensitivity and speciﬁcity values for the outcome
of CIN2+ of the eight tests validated according to the Meijer
protocol (Table 2) were similar to those observed in primary
screening studies. The 90% CI intervals always included unity.
Moreover, the LCIBs for the relative sensitivity (pooled for tests
evaluated in multiple studies or individual if a test was evaluated
in only one study) consistently exceeded 0.90. Also, the LCIBs
for speciﬁcity were 0.98 (Table 4, Figs. 1 and 2). Two further
tests, one evaluated within primary screening and the other
according to the VALGENT protocol, met the accuracy criteria,
namely the MALDI-TOF (which had a relative sensitivity of 0.97
[90% CI, 0.94–1.00] and speciﬁcity of 1.09 [90% CI, 1.01–1.16])
[40] and the GP5+/6+-LMNX (which had a relative sensitivity of
0.98 [90% CI, 0.93–1.03] and speciﬁcity of 1.00 [90% CI,
0.97–1.02]) [41] (See Supplementary Material, chapter 6). The
careHPV Test and the Pretect HPV-Proofer showed signiﬁcantly
inferior sensitivity: careHPV Test/HC2 = 0.86 (90% CI,
0.79–0.94); Pretect HPV-Proofer/HC2 = 0.74 (90% CI,
0.63–0.88). However, the speciﬁcity of the latter tests was
similar or higher than for the standard comparators.
The relative accuracy for the outcome of CIN3+ is detailed
in Table 4 and Supplementary Figs. S2 and S3.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyDiscussionBesides HC2 and GP5+/6+ PCR-EIA validated in randomized
trials, the Abbott RT hrHPV test, cobas 4800 HPV test, BD
Onclarity HPV assay, HPV-Risk assay and the PapilloCheck HPV-
Screening test can also be considered as clinically validated hrHPV
DNA assays usable for primary HPV-based cervical cancer
screening. For all these assays, noninferior sensitivity and speci-
ﬁcity for the outcome CIN2+ and sufﬁcient intra- and inter-
laboratory reproducibility has been demonstrated in at least one
validation study following the Meijer validation protocol. The
Cervista HPV HR Test can be added to this list, although one
study failed to show noninferior speciﬁcity [28]. However, the
pooled relative speciﬁcity compared to HC2was not signiﬁcantly
different from unity (90% CI, 0.98–1.04 with LCIB 0.98). One
in-house quantitative RT-PCR targeting E6/E7DNAsequences of
17 HPV genotypes [25] also fulﬁlled three of the Meijer criteria,
but its interlaboratory reproducibility has not been assessed [42].
Themeta-analysis revealed two further assays (theGP5+/6+ PCR
with Luminex identiﬁcation of high-risk types and the MALDI-
TOF) which were noninferior to the standard comparator
tests with respect to clinical accuracy. Given the absence of
formal checking of reproducibility, these latter two may be
considered partially validated.
Testing for viral mRNA and need for longitudinal data
The APTIMA assay detects E6 or E7 transcripts of 14 high-risk
types. This test showed consistently similar study-speciﬁc andand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 817–826
TABLE 4. Relative accuracy of other HPV tests compared to HC2 (at RLU*‡1) or GP5+6+ PCR–EIA to ﬁnd underlying CIN2+ or
CIN3+ in primary screening
Comparison Outcome
Relative sensitivity
(90% CI)
Relative speciﬁcity
(90% CI)
No.
of studies
APTIMA/HC2 CIN2+ 0.98 (0.95–1.01) 1.04 (1.02–1.07) 6
Abbott RT hrHPV test/HC2 CIN2+ 0.99 (0.96–1.03) 1.02 (1.01–1.02) 3
BD Onclarity/HC2 CIN2+ 0.99 (0.96–1.03) 0.99 (0.98–1.00) 2
Cervista/HC2 CIN2+ 0.98 (0.93–1.03) 1.01 (0.98–1.04) 2
cobas 4800/HC2 CIN2+ 1.00 (0.97–1.03) 0.99 (0.98–1.00) 3
careHPV Test/HC2 CIN2+ 0.86 (0.79–0.94) 1.01 (0.99–1.03) 2
MALDI-TOF/HC2 CIN2+ 0.97 (0.94–1.00) 1.09 (1.01–1.16) 1
Pretect HPV-Proofer/HC2 CIN2+ 0.74 (0.63–0.88) 1.12 (1.10–1.13) 1
qPCR (E6/E7)/HC2 CIN2+ 1.12 (1.02–1.22) 1.01 (1.00–1.03) 1
APTIMA/GP5+/6+ EIA CIN2+ 0.96 (0.92–1.01) 1.01 (0.99–1.03) 1
Abbott RT hrHPV test/GP5+/6+ EIA CIN2+ 0.97 (0.92–1.02) 1.00 (0.98–1.03) 1
GP5+/6+-LMNX/GP5+/6+ EIA CIN2+ 0.98 (0.93–1.03) 1.00 (0.97–1.02) 1
HPV-Risk assay/GP5+/6+ EIA CIN2+ 1.00 (0.95–1.05) 1.01 (0.99–1.02) 1
APTIMA/HC2 CIN3+ 0.98 (0.95–1.02) 1.04 (1.02–1.07) 5
Abbott RT hrHPV test/HC2 CIN3+ 0.99 (0.93–1.05) 1.02 (1.01–1.03) 2
BD Onclarity/HC2 CIN3+ 1.00 (0.92–1.09) 0.99 (0.97–1.00) 1
Cervista/HC2 CIN3+ 0.97 (0.94–1.01) 1.03 (1.02–1.04) 1
cobas 4800/HC2 CIN3+ 1.00 (0.92–1.09) 0.99 (0.98–1.00) 1
careHPV Test/HC2 CIN3+ 0.91 (0.78–1.06) 1.02 (1.00–1.05) 1
MALDI-TOF/HC2 CIN3+ 0.96 (0.93–1.00) 1.02 (1.01–1.03) 1
PapilloCheck/HC2 CIN2+ 0.99 (0.96–1.03) 0.99 (0.98–1.00) 1
Pretect HPV-Proofer/HC2 CIN3+ 0.71 (0.52–0.94) 1.12 (1.10–1.13) 1
GP5+/6+-LMNX/GP5+/6+ EIA CIN3+ 1.00 (0.96–1.04) 1.00 (0.97–1.04) 1
HPV, human papillomavirus; EIA, enzyme immunoassay; CI, conﬁdence interval; qPCR, quantitative PCR; MALDI-TOF, matrix-assisted laser desorption-ionization time-of-ﬂight.
*RLU: relative light units.
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to HC2 (pooled relative sensitivity of 0.98, 90% CI, 0.95–1.01;
pooled relative speciﬁcity of 1.04, 90% CI, 1.02–1.07). More-
over, in a validation study using GP5+/6+ PCR-EIA as
comparator, noninferior accuracy and excellent reproducibility
was evidenced [26]. The similar relative sensitivity and superior
speciﬁcity of APTIMA compared to HC2, observed in primary
screening, is in agreement with the ﬁndings from a previous
meta-analysis on its performance in triage of women with mi-
nor cytologic abnormalities [42]. In both triage of atypical
squamous cells of undetermined signiﬁcance (ASC-US) and
low-grade squamous intraepithelial lesion (LSIL), APTIMA was
as sensitive for detection of CIN2+ as HC2. However, the
former was signiﬁcantly more speciﬁc than HC2 for excluding
cervical precancer (ratio = 1.19 [95% CI, 1.08–1.31] or 1.37
[95% CI, 1.22–1.54, in triage of ASC-US or LSIL, respectively])
[42]. The equivalence criteria for tests in primary screening,
based on relative cross-sectional accuracy, are only valid for
testing for hrHPV DNA and not for other molecular markers
(such as viral RNA, methylation of protein markers) [9]. These
other markers should reach the same level of evidence required
for the original HPV DNA screening tests: the demonstration of
a low cumulative incidence of CIN3+ after a baseline negative
screening test result over a period of at least 5 years similar to
that after a negative screening result with a validated hrHPV
DNA assay [1]. It should be remarked that recently a low
longitudinal risk of CIN3+ (<0.3%) was demonstrated up to 3Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectyears after a negative APTIMA test which was similar to the
risk after a negative HC2 test [43]. This means that screening at
3-year intervals after a negative APTIMA test could be
considered acceptable. For screening with APTIMA at intervals
of 5 years or more, as proposed for validated hrHPV DNA
tests, more data over longer periods will provide additional
reassurance. For hrHPV DNA assays, for which equivalent
cross-sectional accuracy as HC2 or GP5+/6+ PCR-EIA are
accepted as sufﬁcient evidence to allow their use in screening,
the generation of longitudinal data remain useful and corrob-
orate the evidence level. In the ﬁnal report of the ATHENA
trial, it was shown that the cumulative risk of CIN3+ after a
negative cobas 4800 HPV test result was 0.3% (95% CI,
0.1–0.7). For comparison, after negative cytology and after a
co-negative cytology–cobas 4800 HPV test result, the 3-year
risks of CIN3+ were 0.8% (95% CI, 0.5–1.1) and 0.3% (95%
CI, 0.1–0.6), respectively [44]. A low risk of CIN2+ was also
demonstrated in the second screening round 3 years after a
negative baseline Abbott RT hrHPV test (0/1647 = 0.0% vs. 1/
1635 = 0.06% after a negative HC2) [45].
Other performance criteria
Besides accuracy, other fundamental assay characteristics
should be taken into account when the choice of the screening
test is considered. These would include the high throughput
capacity, automation, costs, applicability on samples taken by
the women themselves and the ability to perform ancillaryious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 817–826
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FIG. 1. Relative sensitivity (left) and speciﬁcity (right) of hrHPV DNA or RNA assays compared to HC2 to detect CIN2+ in cervical cancer screening.
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FIG. 2. Relative sensitivity (left) and speciﬁcity (right) of hrHPV DNA or RNA assays compared to the GP5+/6+ PCR-EIA to detect CIN2+ in cervical
cancer screening.
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may be obtained by centralized purchasing tenders addressed
to manufacturers, appealing for a cost-effective, clinically vali-
dated HPV assay to be used in a screening programme [48]. The
potential for ancillary or a priori separate genotyping, the range
of targeted genotypes and the targeted virus gene are other
factors that may play a role in the determination of the
preferred HPV assay. It has been shown that in certain rare
cases of cervical cancer the L1 gene might be disrupted, causing
false-negative screening results when using tests that target this
region [49,50]. However, recent genome-wide proﬁling of HPV
integration in human DNA of cervical cancer patients has
revealed a variety of disruptions in the HPV genome which may
also involve E6 and E7 genes [51]. The requirement of E6/E7
activity for the development and the maintenance of cervical
cancer suggests that possible disruptions in E6/E7 genes would
be accompanied with the presence of virus copies that are not
disrupted in E6/E7. Still, another recent study of a series of
HC2-negative cervical cancers from Spain showed that in cases
which were L1-PCR negative, E7-based PCR was also often
negative [52]. These HPV-negative cancers had a poorer
prognosis than HPV-positive cases [52]. The proportion of such
HPV-negative cancers is low but currently not well known.
Comprehensive genotyping of biopsies from cervical cancer
cases as well as previous archived cytology specimen stored in a
biobank may offer important tools for quality assurance and
monitoring safety within HPV-based screening programmes
[53]. Furthermore, it must be remarked that criteria discussed
in this review only concern HPV testing of a specimen collected
by direct scraping of the surface of the cervix by a clinician. It
has been shown that HPV testing using signal ampliﬁcation as-
says (even with methods clinically validated on clinician
collected material) is less sensitive and speciﬁc on self-collected
compared to clinician-collected samples [46,47]. PCR-based
systems validated on clinician-based cervical samples, on the
other hand, so far have shown similar clinical accuracy on self-
collected and clinician-collected specimen [46,47].
Equivalency criteria of the Meijer guideline
An important issue in the validation process of HPV tests is the
origin of the samples and the status of the cervical cell specimen
included in the series of cases with disease (CIN2+) or nodi-
sease (CIN1). As stated in the Meijer guideline, samples
should be derived from a screening population of women aged
30 or older. This condition was fulﬁlled in eight
[19–23,26,27,29] but not in four other validation studies
[24,25,28,30]. The method of selection of CIN2+ cases was also
variable, with one study including only specimens from women
with CIN3+ [19] and another including samples from women
referred to colposcopy [30]. The choice of relative accuracyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttargets makes the validation process more robust and less
vulnerable to selection biases induced by inclusion of non-
screening specimens. A more important bias may be induced by
arbitrary selection, and the best way to avoid this is to impose
continuous selection of samples (the ﬁrst occurring cases and
controls in a comprehensive screening database linked to an
outcome). The accuracy of ascertainment of nondisease
(CIN1) may inﬂuence the relative speciﬁcity. In most of the
retrieved validation studies, ascertainment of controls was not
well speciﬁed. In one study, it was noted that the control
specimens were selected from women with normal cytology
and with no cytologic abnormality within 12 months [22]. It
cannot be excluded that some CIN2+ may have been missed,
resulting in outcome misclassiﬁcation. An improvement of the
Meijer guideline may be to restrict control specimen to women
who had negative cytology results in two subsequent screening
rounds as proposed in the VALGENT protocol [41]. Further-
more, the policy used to screen the target population (cytology
alone, combined cytology and HPV testing, HPV testing alone)
and the veriﬁcation of screen test positive results may inﬂuence
the validation of HPV assays. For instance, in VALGENT-2
studies [41], diagnostic assessment was only triggered by a
cytology result of high-grade squamous intraepithelial lesion or
repeated ASC-US or LSIL. A certain amount of underdiagnosis
cannot be excluded, giving some advantage to a less sensitive
but more speciﬁc HPV test. For this reason, the VALGENT-2
protocol foresees verifying occurrence of CIN2+ cases in the
next screening round. Conversely, in VALGENT-1 and in the
validation study of the qPCR (E6/E7), diagnostic assessment was
performed after combined HPV and cytology screening where
cytologists had previous knowledge of the results of the HPV
test, possibly resulting in some overdiagnosis which might have
generated an advantage for analytically sensitive assays [54].
Furthermore, the performance validation metric may need
adaptation to be applicable and relevant for immunized
populations.
Addressing all these pitfalls and potential biases will make the
development of future validation guidelines challenging.
Nevertheless, the current Meijer criteria have been of consid-
erable beneﬁt in identifying a group of HPV tests with a good
balance between clinical sensitivity and speciﬁcity, particularly
given the expanding choice of assays.ConclusionThe guideline based on reproducibility and equivalent accu-
racy deﬁned by Meijer et al. [9] is a milestone in HPV-based
cervical cancer screening. The hrHPV DNA assays fully
matching these criteria and which can be recommendedious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 817–826
CMI Arbyn et al. HPV assays and cervical cancer screening 825today in HPV-based cervical cancer screening using clinician-
collected cervical samples are the following: HC2, GP5+/6+
PCR-EIA, Abbott RT hrHPV test, cobas 4800 HPV test,
PapilloCheck HPV-Screening test, BD Onclarity HPV assay
and the HPV-Risk assay. The mRNA-based APTIMA assay also
fully matches the criteria, although further longitudinal data
are awaited. Other HPV DNA tests which partially fulﬁl
these guidelines are the following: Cervista HPV HR Test,
GP5+/6+ PCR-LMNX, an in-house E6/E7 qPCR and
MALDI-TOF. This list of tests recommendable in HPV–based
cervical cancer screening requires regular updating as
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